Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors

Inclusion Criteria: * Any solid tumor that failed standard therapy. * Patient must have evidence for tumor by CT, MRI, PET scan, MIBG scan, serum markers, or tissue sampling. * Age ≤ 21 years. * Karnofsky/Lansky performance status ≥ 50% (Karnofsky score for age\> 16 years and Lansky score for age ≤ 16 years) * ANC≥ 1000 at least 24 hours off GCSF * Platelets ≥ 75k at least one week off platelet transfusions * Hg≥ 8g/dL at least one week off PRBC transfusion * AST ≤ 3 x the upper limit of normal * ALT ≤ 3 x the upper limit of normal * Total bilirubin ≤ 2.0 mg/dl * serum creatinine ≤ 1.5 x the upper limit of normal for age, or calculated creatinine clearance or nuclear GFR ≥ 70 ml/min/1.73 m2. * ≥ 3 weeks since last non-nitrosourea chemotherapy * ≥ 6 weeks since last nitrosoureas * ≥ 4 weeks since last RT * Patients must agree to practice adequate contraception. Females of childbearing potential must have a negative B-HCG pregnancy test documented within 14 days prior to drug initiation. Females must not be breast feeding. * Patients must be able to swallow tablets whole Exclusion Criteria: * Pregnancy * Patients must not have active infection or serious intercurrent medical illness. * HIV-Positive patients receiving combination anti-retroviral therapy are excluded from the study due to possible retro-viral drug interactions. HIV testing not required. * Patients must not be taking EIAEDs. If patients were previously EIAEDs that have been discontinued, patients must have been off the agent for at least 2 weeks prior to registration.